Retrospective correlation analysis of plasma Immunoglobulin G and clinical performance in CIDP

Retrospective correlation analysis of plasma Immunoglobulin G and clinical performance in CIDP

Background Chronic inflammatory demyelinating polyneuropathy (CIDP) can be successfully treated with immunoglobulin either intravenously (IVIG) or subcutaneously (SCIG). Measurement of plasma immunoglobulin G levels (P-IgG) and its correlation to clinical improvement has shown conflicting results. T...

Full description

Bibliographic Details
Main Authors:	Lars Kjøbsted Markvardsen, Stine Bruun-Sørensen, Ingelise Christiansen, Henning Andersen
Format:	Article
Language:	English
Published:	PeerJ Inc. 2019-05-01
Series:	PeerJ
Subjects:	Muscle strength CIDP Plasma immunoglobulin G IVIG SCIG
Online Access:	https://peerj.com/articles/6969.pdf

Similar Items

Immunoglobulin utilization in Canada: a comparative analysis of provincial guidelines and a scoping review of the literature
by: Megan Harmon, et al.
Published: (2023-09-01)

Initial intravenous immunoglobulin doses should be based on adjusted body weight in obese patients with primary immunodeficiency disorders
by: Rohan Ameratunga
Published: (2017-12-01)

Clinical and laboratory parameter analysis in patients with common Variable Immunodeficiency
by: Krtinić Danka, et al.
Published: (2022-01-01)

The Natural History of Untreated Primary Hypogammaglobulinemia in Adults: Implications for the Diagnosis and Treatment of Common Variable Immunodeficiency Disorders (CVID)
by: Rohan Ameratunga, et al.
Published: (2019-07-01)

Immunoglobulin replacement therapies in inborn errors of immunity: a review
by: Archan Sil, et al.
Published: (2024-02-01)

Clinical and Neurophysiological Follow-Up of Chronic Inflammatory Demyelinating Polyneuropathy Patients Treated with Subcutaneous Immunoglobulins: A Real-Life Single Center Study
by: Paolo Alonge, et al.
Published: (2022-12-01)

Is dosing of therapeutic immunoglobulins optimal? – A review of a 3-decade long debate in Europe.
by: Jacqueline eKerr, et al.
Published: (2014-12-01)

Parameters Associated with the Required Drug Dose of Intravenous Immunoglobulin in Stable Chronic Inflammatory Demyelinating Polyradiculoneuropathy
by: Ludger Feyen, et al.
Published: (2023-03-01)

The Cost Effectiveness of Immunoglobulin vs. Hematopoietic Stem Cell Transplantation for CIDP
by: Richard K. Burt, et al.
Published: (2021-03-01)

On the dark side of therapies with immunoglobulin concentrates. The adverse events
by: Peter J. Spaeth, et al.
Published: (2015-02-01)

Delivery of subcutaneous immunoglobulin by rapid “push” infusion for primary immunodeficiency patients in Manitoba: a retrospective review
by: Graham Walter, et al.
Published: (2020-05-01)

CIDP mimics: a case series
by: Orly Moshe-Lilie, et al.
Published: (2021-02-01)

Intravenous Immunoglobulin Treatment Patterns and Outcomes in Patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy: A US Claims Database Analysis
by: Colin Anderson-Smits, et al.
Published: (2023-05-01)

Real-World Experiences With Facilitated Subcutaneous Immunoglobulin Substitution in Patients With Hypogammaglobulinemia, Using a Three-Step Ramp-Up Schedule
by: Nina B. Hustad, et al.
Published: (2021-04-01)

Using the K/BxN mouse model of endogenous, chronic, rheumatoid arthritis for the evaluation of potential immunoglobulin-based therapeutic agents, including IVIg and Fc-μTP-L309C, a recombinant IgG1 Fc hexamer
by: Bonnie J. B. Lewis, et al.
Published: (2019-12-01)

Access to Immunoglobulin Treatment for CIDP Patients During the COVID-19 Pandemic
by: Vincent Brissette, et al.
Published: (2023-08-01)

Primary Immune Deficiency: Patients’ Preferences for Replacement Immunoglobulin Therapy
by: Juan Marcos Gonzalez, et al.
Published: (2022-02-01)

Analysis of specific IgG titres against tick borne encephalitis in patients with primary antibody deficiency under immunoglobulin substitution therapy: impact of plasma donor origin
by: Sigune eGoldacker, et al.
Published: (2015-01-01)

Immunoglobulin replacement therapy in patients with immunodeficiencies: impact of infusion method on patient-reported outcomes
by: Rajiv Mallick, et al.
Published: (2022-12-01)

Is nerve biopsy useful in diagnosis of CIDP?
by: Ioana Mindruta, et al.
Published: (2011-03-01)

The Misdiagnosis of CIDP: A Review
by: Jeffrey A. Allen
Published: (2020-03-01)

Chronic Inflammatory Demyelinating Polyradiculoneuropathy: Current Therapeutic Approaches and Future Outlooks
by: Rajabally YA
Published: (2024-02-01)

Hyaluronidase facilitated subcutaneous immunoglobulin in primary immunodeficiency
by: Jolles S
Published: (2013-09-01)

Intravenous immunoglobulin remain a source of bias in the interpretation of infectious disease serology among clinicians
by: A.K. Van der Bij, et al.
Published: (2020-12-01)

Fatigue, depression, and product tolerability during long-term treatment with intravenous immunoglobulin (Gamunex® 10%) in patients with chronic inflammatory demyelinating polyneuropathy
by: Juliane Klehmet, et al.
Published: (2023-05-01)

Quantitative Analysis of Electrophysiological Characteristics of CIDP and CMT Type 1: Sensory Nerve Research
by: Ji-Hyuk Kang
Published: (2021-06-01)

Intravenous Immunoglobulin Protects Against Severe Pandemic Influenza Infection
by: Steven Rockman, et al.
Published: (2017-05-01)

The therapeutic window of intravenous immunoglobulin (IVIG) and its correlation with clinical outcomes in Kawasaki disease: a systematic review and meta-analysis
by: Zheng Li, et al.
Published: (2023-04-01)

Pathophysiology of the Different Clinical Phenotypes of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
by: Edyta Dziadkowiak, et al.
Published: (2021-12-01)

Clinical Efficacy, Safety and Tolerability of a New Subcutaneous Immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the Treatment of Patients With Primary Immunodeficiencies
by: Roger H. Kobayashi, et al.
Published: (2019-02-01)

Plasma therapy: a passive resistance against the deadliest
by: Anita Hansda, et al.
Published: (2022-04-01)

Corrigendum: Clinical efficacy, safety and tolerability of a new subcutaneous immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the treatment of patients with primary immunodeficiencies
by: Roger H. Kobayashi, et al.
Published: (2022-12-01)

Protocol of comparison of the effects of single plasma exchange and double filtration plasmapheresis on peripheral lymphocyte phenotypes in patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy: a monocentric prospective study with single-case experimental design
by: O. Moranne, et al.
Published: (2022-08-01)

Severe CIDP-MGUS responsive to Rituximab
by: Andreas Posa, et al.
Published: (2020-06-01)

Potential intravenous immunoglobulin-induced optic disc edema
by: Anna K. Britton, et al.
Published: (2022-09-01)

Pregnancy associated anti-TIF1 dermatomyositis responsive to intravenous immunoglobulin
by: Jason Kieffer, MD, et al.
Published: (2024-03-01)

Timing of infections in patients with primary immunodeficiencies treated with intravenous immunoglobulin (IVIg)
by: Parwinder K. Gill, et al.
Published: (2018-08-01)

Time for a standardized diagnostic response test in patients with chronic inflammatory demyelinating polyradiculoneuropathy?
by: Fabian Szepanowski, et al.
Published: (2023-11-01)

Treatment of immunoglobulin-resistant kawasaki disease: a Bayesian network meta-analysis of different regimens
by: Yan Pan, et al.
Published: (2023-07-01)

Electrophysiological assessment of Chronic Inflammatory Demyelinating Peripheral Polyradiculoneuropathy(CIDP) in Patients with Diabetes Mellitus
by: Marwa S. Suhail, et al.
Published: (2014-10-01)